ICICI Direct: Hikal Logs Decent Q2 Performance Despite Deferred Orders
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Hikal Ltd.’s Q2 FY21 revenues grew a decent 15.8% YoY to Rs 372 crore on the back of 34.1% YoY growth in pharma segment to Rs 279 crore.
Crop protection segment fell 17.9% YoY to Rs 93 crore due to deferral of Rs 40 crore worth of shipment to Q3 FY21.
Ebitda for the quarter came in at Rs 70 crore, up 19.6% YoY (including Covid-19 related expenses of Rs 1.1 crore).
Ebitda margins expanded 58 basis points YoY to 18.8% due to lower staff and other expenses, partly offset by lower gross margins.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.